A three-center cross-sectional study with 17 patients who fulfilled the EULAR/PRINTO/PReS criteria for c-TA and who underwent [18F]F-FDG-PET/MRI was previously performed. Herein we compared patients/vessels with positive PET (arterial wall 18F-FDG uptake higher than liver) and positive MRA (arterial wall thickening with contrast-enhancement)-group 1, with those with positive PET but negative MRA-group 2.
Median disease duration of 17 c-TA patients was 10.4 years. Nine patients were classified as group 1 and six as group 2. Median of metabolic inflammatory volume (MIV) of all arterial segments was significantly higher in group 1 (2346 vs. 1177 cm3; p = 0.036). Fifty-four (19%) from 284 available arterial segments presented positive findings in vessel wall in one or both images. Positive findings were concordant between PET and MRA in only 13% arterial segments (group 1); most changes (28-59.6%) that were discordant between both images, were positive in PET and negative in MRA (group 2).
Our study demonstrated that [18F]F-FDG-PET/MRI added information about inflammation in vessel wall of c-TA patients. Prospective multicenter studies are needed in order to get solid data to guide immunosuppressive tapering and withdrawal.
先前对17例符合EULAR/PRINTO/PReSc-TA标准并接受[18F]F-FDG-PET/MRI的患者进行了一项三中心横断面研究。在这里,我们比较了PET阳性(动脉壁18F-FDG摄取高于肝脏)和MRA阳性(对比增强的动脉壁增厚)组1的患者/血管,PET阳性但MRA阴性的患者组2。
17例c-TA患者的中位病程为10.4年。9例患者被归类为第1组,6例被归类为第2组。在第1组中,所有动脉段的代谢性炎症体积(MIV)的中位数均显着较高(2346vs.1177cm3;p=0.036)。在一个或两个图像中,来自284个可用动脉段的54个(19%)在血管壁中呈现阳性发现。PET和MRA的阳性结果仅在13%的动脉段(第1组)之间是一致的;大多数变化(28-59.6%)在两个图像之间是不一致的,PET阳性,MRA阴性(第2组)。
我们的研究表明,[18F]F-FDG-PET/MRI增加了c-TA患者血管壁炎症的信息。需要进行前瞻性多中心研究,以获得可靠的数据来指导免疫抑制逐渐减少和戒断。